TY - BOOK ID - 124941734 TI - CADTH Canadian Drug Expert Review Committee final recommendation : Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.) : indication: asthma PY - 2016 PB - Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, DB - UniCat KW - Cost effectiveness. UR - https://www.unicat.be/uniCat?func=search&query=sysid:124941734 AB - ER -